This epigenetic signature could be a putative target for the development of novel epigenetic-based therapies and could help in explaining the molecular mechanisms characterizing ALL infants with KMT2A/AFF1 fusions. The gene discussed is AFF1; the disease is acute lymphoblastic leukemia.